search
Back to results

Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM)

Primary Purpose

Asthma, Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)

Status
Recruiting
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Blood sampling
Nasosorption
Oral sampling
Bronchoscopy
Nasal biopsy
Nasal sampling
Nasal mucosa mRNA sampling
Pregnancy test
Medical history of patients, demographic data, concomitant medication, questionnaire
UPSIT smell test
Spirometry
FeNO
Lung X-Ray
Sponsored by
Medical University of Vienna
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Asthma focused on measuring Asthma, Chronic Rhinosinusitis (CRS), CRS with Nasal Polyps, CRS without Nasal Polyps, Inflammatory profile, Type 2 inflammation

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

All patients who

  • 18-99 years of age
  • have a recorded clinical diagnosis of asthma (ICD-10 Code: J45)
  • undergo moderate-serve asthma treatment according to GINA/DAL treatment step 4 or step 5 without oral corticosteroid or monoclonal antibody therapy
  • Asthma treatment for a minimum of 12 weeks prior to screening visit

    • Group 1 and 2 - T2-high asthma with or without polyps:
  • FeNO > 25 ppB
  • had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months
  • Group with polyps: Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)

    • Group 3 - CRSwNP in absence of asthma:
  • Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines
  • Evidence of Type 2 inflammation: eosinophils >= 250 cells/µl measured in the blood OR total IgE >100 kU/L at the screening visit
  • Absence of asthma and N-ERD
  • Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a wash out period of 5 half-lives or at least 3 months have passed

Exclusion Criteria:

  • Pregnancy (as determined by ß-HCG test)
  • Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity
  • Patients undergoing chronic oral corticosteroid therapy
  • Patients with any other confounding underlying lung disorder including but not limited to:

    • Bronchiectasis, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, emphysema, primary ciliary dyskinesia
    • Cystic fibrosis, any known parasitic infections, and lung cancer
  • Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia including but not limited to: Eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillus, and hypereosinophilic syndrome
  • A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
  • Patients with clinically meaningful comorbidity as determined by the evaluating committee
  • Patients with a history of exacerbation of chronic rhinosinusitis or asthma 4 weeks prior to any visit
  • Intake of a burst of systemic corticosteroids 4 weeks prior to any visit.
  • Immunosuppressive treatment (e.g. cyclosporine)
  • Drug and alcohol abuses
  • Current smoker
  • Former smoker if stopped smoking <6 months and/or has >10 pack-years

Sites / Locations

  • Allgemeines Krankenhaus (AKH) WienRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

T2-high asthma with nasal polyps

T2-high asthma without nasal polyps

CRSwNP in absence of asthma

Arm Description

FeNO > 25 ppB Had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines) Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed

FeNO > 25 ppB Had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months Absence of NP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines) Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed

Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines26 Evidence of Type 2 inflammation: blood eosinophils >= 250 cells/µl measured in the blood OR total IgE >100 kU/L26 at the screening visit Absence of asthma and N-ERD Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed

Outcomes

Primary Outcome Measures

Inflammatory profile in different sections of the airways
Concentration of selected inflammatory mediators in T2-high asthmatic patients with and without polyps and in patients with CRSwNP in absence of asthma

Secondary Outcome Measures

Endotype and immunological profile of CRSwNP
Number of patients with specific endotypes of polyps and concentration of selected inflammatory mediators of various anatomic locations in the airways both in tissue and secretion samples in patients suffering from T2-high asthma with or without CRSwNP and in patients with CRSwNP in absence of asthma.
Microbiome composition in nose, oropharynx and bronchi in T2-high asthmatic patients with and without CRSwNP, N-ERD compared to patients with CRSwNP in absence of asthma
Number of different bacterial strains in different anatomical locations in asthmatic patients with and without polyps and CRSwNP patients in absence of asthma and to evaluate differences.

Full Information

First Posted
August 5, 2021
Last Updated
November 10, 2021
Sponsor
Medical University of Vienna
search

1. Study Identification

Unique Protocol Identification Number
NCT05009758
Brief Title
Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps
Acronym
PREMIUM
Official Title
Moving Towards PREcision Medicine In United Airways Disease: Unraveling inflaMmatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM) - a Descriptive Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
September 2022 (Anticipated)
Study Completion Date
September 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Vienna

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Asthma and chronic rhinosinusitis (CRS) are inflammatory diseases of the respiratory tract, asthma from the lower part, and CRS, from the upper part. In theory, these parts are correlated as if they are one single organ, namely "united airways", which means that if one is affected by any condition, the other might be impacted as well. However, this relationship has not yet been described down to the cellular and molecular levels. By investigating patients that have (1) asthma and CRS with nasal polyp, (2) asthma and CRS without nasal polyp, and (3) just CRS with nasal polyp, we aim to determine the correlation of the upper and lower part of the respiratory tract. At first, the characterization of disease will be determined by established clinical criteria, such as lung function, blood analysis for the presence of eosinophils (a type of white cells), and nasal polyp score. To continue, in-depth analysis of nose, oropharynx, and lung samples will help gain information about the inflammatory profile and local microbiome of the three different groups of patients through molecular and cellular assays. The results of this study will help to describe the hypothesis of the united airways which will provide better guidance for medical treatment of asthma and CRS with or without polyp, thus improving the life quality of patients.
Detailed Description
Background Both, asthma and chronic rhinosinusitis (CRS) are inflammatory conditions of the airways. The prevalence of asthma - with its cardinal symptoms wheezing, breathlessness, chest tightness, and coughing - has risen over the past decades not only in industrial but also in developing countries. For instance, about 8% of the United States' population and 8.2% of Europeans are diagnosed with asthma. Chronic rhinosinusitis with (CRSwNP) and without nasal polyps (CRSsNP) is a condition affecting up to 16% and 11% of the US and European population, respectively3. Both diseases, asthma and CRS, can severely impair quality of life as well as productivity and therefore embody an immense socioeconomic burden. Despite the distinction of the respiratory tract in the upper and lower airways, both parts are anatomically and immunologically related. This led to the concept of "United airway diseases" assuming that upper and lower airways form a single organ. Consequently, inflammation in the upper affects the lower respiratory tract and vice versa. This concept initially described in the context of allergic respiratory disease can also be extended to the link between sinonasal and lower airway diseases. Accordingly, the association between asthma and CRS prevalence has been unambiguously shown in epidemiological studies: around 20% of CRSsNP patients and around 48% of CRSwNP patients suffer from asthma. Conversely, nasal polyposis is detected in 19 to 25% of asthmatics. In cases of severe asthma, even up to 54% of patients were reported to have a history of nasal polyposis. However, the pathophysiological mechanism underlying the association of asthma and CRS has been poorly investigated so far. Based on the predominant inflammatory profile, asthma can be separated into T2-high and T2-low endotypes. Thereby, around 60% of severe asthma patients show a T2-high profile. The picture is becoming even more complex regarding classifications of CRS. Phenotypically we distinguish between CRSsNP and CRSwNP. However, up to 10 different endotypes of CRS can be defined based on various different inflammatory markers in nasal polyps or nasal secretions. Approaches to characterize endotypes describing conditions involving both asthma and CRS have barely been made so far. On a cellular and protein level, it seems that higher concentrations of Staphylococcus enterotoxin-specific IgE, total IgE and eosinophil cationic protein in nasal polyp tissue are indicators for a higher risk of asthma. Furthermore, it was observed that patients with CRS and eosinophilic asthma (as determined by FeNO levels only) show high numbers of eosinophils in their nasal polyps. This nasal polyp eosinophilia was associated with a more severe asthma phenotype as well as larger polyps and a significantly higher nasal polyp recurrence rate compared to non-eosinophilic patients. However, up to this point, no study investigated whether inflammatory profiles in polyps and asthmatic lungs correspond and how inflammatory profiles of patients suffering from asthma with or without polyps may differ. Novel antibody-based therapies targeting mediators of type 2 immune response are constantly emerging as new treatment options for patients with severe chronic airway diseases. Therapeutic antibodies targeting IgE or IL-4/IL-13, IL-5, or IL-5 receptor-mediated pathways are currently licensed for the treatment of asthma but have also successfully been used to treat CRSwNP to some extent. In this respect, anti-IgE (omalizumab) and anti-IL4α receptor (dupilumab) specific monoclonal antibodies have recently been licensed for the treatment of nasal polyps and CRSwNP respectively. Antibodies targeting molecules further upstream in the inflammatory cascade such as TSLP or IL-33 are currently under development. Anti-TSLP antibodies showed first promising results in clinical trials including patients suffering from uncontrolled asthma. Despite targeting molecular pathways involved in the pathogenesis of both diseases, some monoclonal antibodies such as reslizumab are effective in treating asthma but fail to significantly ameliorate nasal polyposis. Interestingly, a post-hoc responder analysis showed that the group of patients with high baseline IL-5 levels in nasal secretions improved upon reslizumab treatment, while the other patient groups did not. These findings illustrate the urgent need to better understand the pathomechanism and potential links underlying both diseases in order to choose the right therapy for the right patient. Study rationale In this study, we aim to unravel the pathophysiological mechanisms underlying T2-high asthma with or without nasal polyposis. Therefore, we plan to thoroughly examine T2-high asthmatic patients with and without nasal polyposis at the cellular and molecular level and compare them to patients suffering from eosinophilic polyps in the absence of asthma. Deep analysis of nose, oropharynx, and lung samples will yield information on inflammatory patterns at protein and mRNA level, cellular tissue architecture in the different disease subtypes as well as microbiome composition. This pilot study will help to unravel underlying pathomechanisms in these united airway diseases and, therefore, provide a rationale for new therapy approaches including biologicals. Study objectives In this study we plan to: evaluate the inflammatory profile in different sections of the airways; evaluate the endotype and immunological profile of CRSwNP (when applicable); determine the microbiome composition in nose, oropharynx, and bronchi in T2-high asthmatic patients with and without CRSwNP, N-ERD compared to patients with CRSwNP in absence of asthma

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma, Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis), Nasal Polyps
Keywords
Asthma, Chronic Rhinosinusitis (CRS), CRS with Nasal Polyps, CRS without Nasal Polyps, Inflammatory profile, Type 2 inflammation

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Subjects attending the outpatient clinic of the Department of Othorrinolaringology or Pulmonology of the Medical University of Vienna for symptoms of asthma or CRS with nasal polyposis will be recruited during their routine visit. After informing patients about the scopes of the study, they will be invited for a screening visit. During this visit, patients will be informed about the nature of the study and asked whether they are willing to participate. After signing the informed consent, they will undergo a screening visit to determine their eligibility for the study and group allotment. The following parameters will be recorded at the screening visit: medical history including concomitant medication, nasal examination (endoscopy), lung function and FeNO measurement, blood draw (eosinophil levels and for exploratory parameters). Thereafter, eligible patients will attend a single study visit for the collection of all clinical parameters and samples.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
T2-high asthma with nasal polyps
Arm Type
Active Comparator
Arm Description
FeNO > 25 ppB Had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines) Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed
Arm Title
T2-high asthma without nasal polyps
Arm Type
Active Comparator
Arm Description
FeNO > 25 ppB Had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months Absence of NP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines) Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed
Arm Title
CRSwNP in absence of asthma
Arm Type
Active Comparator
Arm Description
Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines26 Evidence of Type 2 inflammation: blood eosinophils >= 250 cells/µl measured in the blood OR total IgE >100 kU/L26 at the screening visit Absence of asthma and N-ERD Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed
Intervention Type
Procedure
Intervention Name(s)
Blood sampling
Intervention Description
Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
Intervention Type
Procedure
Intervention Name(s)
Nasosorption
Intervention Description
Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
Intervention Type
Procedure
Intervention Name(s)
Oral sampling
Intervention Description
For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
Intervention Type
Procedure
Intervention Name(s)
Bronchoscopy
Intervention Description
The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
Intervention Type
Procedure
Intervention Name(s)
Nasal biopsy
Intervention Description
Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
Intervention Type
Procedure
Intervention Name(s)
Nasal sampling
Intervention Description
Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
Intervention Type
Procedure
Intervention Name(s)
Nasal mucosa mRNA sampling
Intervention Description
Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
Intervention Type
Diagnostic Test
Intervention Name(s)
Pregnancy test
Intervention Description
In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
Intervention Type
Other
Intervention Name(s)
Medical history of patients, demographic data, concomitant medication, questionnaire
Intervention Description
Patients will be asked for their medical history including demographic data and concomitant medication. Details will be noted in the source data file. Furthermore, patients will receive a questionnaire including tools to assess QOL impairment by CRS and asthma
Intervention Type
Diagnostic Test
Intervention Name(s)
UPSIT smell test
Intervention Description
University of Pennsylvania Smell Identification Test (UPSIT) smell test will be performed by the patients during the study. It consists of 40 questions in 4 different booklets. The patient needs to scratch a sniff strip with the microencapsulated odorant using a pencil and mark his choice on four-choice multiple-choice questions. The test is then scored by the study team out of the 40 items.
Intervention Type
Procedure
Intervention Name(s)
Spirometry
Intervention Description
Lung function will be measured by spirometry in the lung function unit of the Department of Pulmonology. Spirometry will be performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines by authorized and properly certified personal.
Intervention Type
Procedure
Intervention Name(s)
FeNO
Intervention Description
Airway inflammation will be evaluated using a standardized single-breath FeNO test in accordance with the lung function unit of the Department of Pulmonology. A single exhalation technique recommended by the manufacturer will be followed. The FeNO measurements will not be performed within 2 weeks of a respiratory infection. The FeNO test will be performed prior to spirometry. Subjects should not eat or drink 1 hour prior to having the FeNO test. Subjects should not use their rescue SABA medication (e.g., albuterol/salbutamol) within 6 hours of the measurement. Inhaled bronchodilators (including ICS/LABA) should be withheld for the effect duration specific to the bronchodilator. If not, the assessment should be postponed till after the required time has passed since the meal or drink or bronchodilator inhalation. The NIOX VERO® Airway Inflammation Monitor will be used to measured FeNO in the lung function unit of the Department of Pulmonology.
Intervention Type
Procedure
Intervention Name(s)
Lung X-Ray
Intervention Description
After the bronchoscopy, a lung x-ray will be performed and patients will stay overnight in the ward of the Department of Pulmonology.
Primary Outcome Measure Information:
Title
Inflammatory profile in different sections of the airways
Description
Concentration of selected inflammatory mediators in T2-high asthmatic patients with and without polyps and in patients with CRSwNP in absence of asthma
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Endotype and immunological profile of CRSwNP
Description
Number of patients with specific endotypes of polyps and concentration of selected inflammatory mediators of various anatomic locations in the airways both in tissue and secretion samples in patients suffering from T2-high asthma with or without CRSwNP and in patients with CRSwNP in absence of asthma.
Time Frame
2 years
Title
Microbiome composition in nose, oropharynx and bronchi in T2-high asthmatic patients with and without CRSwNP, N-ERD compared to patients with CRSwNP in absence of asthma
Description
Number of different bacterial strains in different anatomical locations in asthmatic patients with and without polyps and CRSwNP patients in absence of asthma and to evaluate differences.
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients who 18-99 years of age have a recorded clinical diagnosis of asthma (ICD-10 Code: J45) undergo moderate-serve asthma treatment according to GINA/DAL treatment step 4 or step 5 without oral corticosteroid or monoclonal antibody therapy Asthma treatment for a minimum of 12 weeks prior to screening visit Group 1 and 2 - T2-high asthma with or without polyps: FeNO > 25 ppB had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months Group with polyps: Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines) Group 3 - CRSwNP in absence of asthma: Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines Evidence of Type 2 inflammation: eosinophils >= 250 cells/µl measured in the blood OR total IgE >100 kU/L at the screening visit Absence of asthma and N-ERD Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a wash out period of 5 half-lives or at least 3 months have passed Exclusion Criteria: Pregnancy (as determined by ß-HCG test) Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity Patients undergoing chronic oral corticosteroid therapy Patients with any other confounding underlying lung disorder including but not limited to: Bronchiectasis, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, emphysema, primary ciliary dyskinesia Cystic fibrosis, any known parasitic infections, and lung cancer Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia including but not limited to: Eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillus, and hypereosinophilic syndrome A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study Patients with clinically meaningful comorbidity as determined by the evaluating committee Patients with a history of exacerbation of chronic rhinosinusitis or asthma 4 weeks prior to any visit Intake of a burst of systemic corticosteroids 4 weeks prior to any visit. Immunosuppressive treatment (e.g. cyclosporine) Drug and alcohol abuses Current smoker Former smoker if stopped smoking <6 months and/or has >10 pack-years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Julia Eckl-Dorna, PhD
Phone
+4314040034380
Email
julia.eckl-dorna@meduniwien.ac.at
First Name & Middle Initial & Last Name or Official Title & Degree
Sven Schneider, MD
Phone
+4314040034380
Email
sven.schneider@meduniwien.ac.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julia Eckl-Dorna, PhD
Organizational Affiliation
Medical University of Vienna
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sven Schneider, MD
Organizational Affiliation
Medical University of Vienna
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marco Idzko, MD
Organizational Affiliation
Medical University of Vienna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Allgemeines Krankenhaus (AKH) Wien
City
Wien
ZIP/Postal Code
1090
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marianne Rocha Hasler, PhD
Phone
014040034380
Email
marianne.rochahasler@meduniwien.ac.at
First Name & Middle Initial & Last Name & Degree
Julia Eckl-Dorna, PhD
Phone
014040034380
Email
julia.eckl-dorna@meduniwien.ac.at
First Name & Middle Initial & Last Name & Degree
Sven Schneider, MD
First Name & Middle Initial & Last Name & Degree
Marco Idzko, MPVD
First Name & Middle Initial & Last Name & Degree
Julia Eckl-Dorna, PhD

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
32020334
Citation
Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semin Immunopathol. 2020 Feb;42(1):5-15. doi: 10.1007/s00281-020-00785-1. Epub 2020 Feb 4.
Results Reference
background
PubMed Identifier
24000245
Citation
Gibson GJ, Loddenkemper R, Lundback B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J. 2013 Sep;42(3):559-63. doi: 10.1183/09031936.00105513. No abstract available.
Results Reference
background
PubMed Identifier
28474799
Citation
Hellings PW, Klimek L, Cingi C, Agache I, Akdis C, Bachert C, Bousquet J, Demoly P, Gevaert P, Hox V, Hupin C, Kalogjera L, Manole F, Mosges R, Mullol J, Muluk NB, Muraro A, Papadopoulos N, Pawankar R, Rondon C, Rundenko M, Seys SF, Toskala E, Van Gerven L, Zhang L, Zhang N, Fokkens WJ. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017 Nov;72(11):1657-1665. doi: 10.1111/all.13200. Epub 2017 Jun 2.
Results Reference
background
PubMed Identifier
26010063
Citation
Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015 Sep;5 Suppl 1:S7-10. doi: 10.1002/alr.21547. Epub 2015 May 23.
Results Reference
background
PubMed Identifier
25640115
Citation
Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: A systematic review. Laryngoscope. 2015 Jul;125(7):1547-56. doi: 10.1002/lary.25180. Epub 2015 Jan 30.
Results Reference
background
PubMed Identifier
27257389
Citation
Giavina-Bianchi P, Aun MV, Takejima P, Kalil J, Agondi RC. United airway disease: current perspectives. J Asthma Allergy. 2016 May 11;9:93-100. doi: 10.2147/JAA.S81541. eCollection 2016.
Results Reference
background
PubMed Identifier
10992552
Citation
Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic aspects. Thorax. 2000 Oct;55 Suppl 2(Suppl 2):S26-7. doi: 10.1136/thorax.55.suppl_2.s26. No abstract available.
Results Reference
background
PubMed Identifier
29869791
Citation
Yii ACA, Tay TR, Choo XN, Koh MSY, Tee AKH, Wang DY. Precision medicine in united airways disease: A "treatable traits" approach. Allergy. 2018 Oct;73(10):1964-1978. doi: 10.1111/all.13496. Epub 2018 Jul 10.
Results Reference
background
PubMed Identifier
26678021
Citation
Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol. 2016 Apr;6(4):373-7. doi: 10.1002/alr.21674. Epub 2015 Dec 17.
Results Reference
background
PubMed Identifier
29945606
Citation
Philpott CM, Erskine S, Hopkins C, Kumar N, Anari S, Kara N, Sunkaraneni S, Ray J, Clark A, Wilson A; CRES group; Erskine S, Philpott C, Clark A, Hopkins C, Robertson A, Ahmed S, Kara N, Carrie S, Sunkaraneni V, Ray J, Anari S, Jervis P, Panesaar J, Farboud A, Kumar N, Cathcart R, Almeyda R, Khalil H, Prinsley P, Mansell N, Salam M, Hobson J, Woods J, Coombes E. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir Res. 2018 Jun 27;19(1):129. doi: 10.1186/s12931-018-0823-y.
Results Reference
background
PubMed Identifier
22691577
Citation
Ahmadiafshar A, Farjd HR, Moezzi F, Mousavinasab N. Nasal polyposis in patients with asthma and allergic rhinitis. J Laryngol Otol. 2012 Aug;126(8):780-3. doi: 10.1017/S0022215112000771. Epub 2012 Jun 12.
Results Reference
background
PubMed Identifier
27730197
Citation
de Groot JC, Storm H, Amelink M, de Nijs SB, Eichhorn E, Reitsma BH, Bel EH, Ten Brinke A. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016 May 26;2(2):00100-2015. doi: 10.1183/23120541.00100-2015. eCollection 2016 Apr.
Results Reference
background
PubMed Identifier
23806634
Citation
Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, ten Brinke A, Bel EH. Severe adult-onset asthma: A distinct phenotype. J Allergy Clin Immunol. 2013 Aug;132(2):336-41. doi: 10.1016/j.jaci.2013.04.052. Epub 2013 Jun 24.
Results Reference
background
PubMed Identifier
31735516
Citation
Narendra D, Blixt J, Hanania NA. Immunological biomarkers in severe asthma. Semin Immunol. 2019 Dec;46:101332. doi: 10.1016/j.smim.2019.101332. Epub 2019 Nov 14.
Results Reference
background
PubMed Identifier
26949058
Citation
Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, Forster-Ruhrmann U, Kowalski ML, Olszewska-Ziaber A, Holtappels G, De Ruyck N, Wang X, Van Drunen C, Mullol J, Hellings P, Hox V, Toskala E, Scadding G, Lund V, Zhang L, Fokkens W, Bachert C. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016 May;137(5):1449-1456.e4. doi: 10.1016/j.jaci.2015.12.1324. Epub 2016 Mar 4.
Results Reference
background
PubMed Identifier
29452200
Citation
Turner JH, Chandra RK, Li P, Bonnet K, Schlundt DG. Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines. J Allergy Clin Immunol. 2018 May;141(5):1895-1897.e7. doi: 10.1016/j.jaci.2018.02.002. Epub 2018 Feb 13. No abstract available.
Results Reference
background
PubMed Identifier
20810157
Citation
Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, Lin P, Bousquet J, Van Steen K. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010 Nov;126(5):962-8, 968.e1-6. doi: 10.1016/j.jaci.2010.07.007.
Results Reference
background
PubMed Identifier
28126433
Citation
Wu D, Li L, Zhang M, Wang J, Wei Y. Two inflammatory phenotypes of nasal polyps and comorbid asthma. Ann Allergy Asthma Immunol. 2017 Mar;118(3):318-325. doi: 10.1016/j.anai.2016.12.018. Epub 2017 Jan 23.
Results Reference
background
PubMed Identifier
31090937
Citation
Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, Canonica GW, Deneyer L, Desrosiers M, Diamant Z, Han J, Heffler E, Hopkins C, Jankowski R, Joos G, Knill A, Lee J, Lee SE, Marien G, Pugin B, Senior B, Seys SF, Hellings PW. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019 Dec;74(12):2312-2319. doi: 10.1111/all.13875. Epub 2019 Jul 15.
Results Reference
background
PubMed Identifier
32064642
Citation
Agache I, Rocha C, Beltran J, Song Y, Posso M, Sola I, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Makela M, Martin IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Perez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1043-1057. doi: 10.1111/all.14235.
Results Reference
background
PubMed Identifier
31073812
Citation
Agarwal A, Spath D, Sherris DA, Kita H, Ponikau JU. Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed? Clin Rev Allergy Immunol. 2020 Oct;59(2):141-149. doi: 10.1007/s12016-019-08734-z.
Results Reference
background
PubMed Identifier
33872587
Citation
Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7. Epub 2021 Apr 16.
Results Reference
background
PubMed Identifier
31743962
Citation
Agache I, Cojanu C, Laculiceanu A, Rogozea L. Critical Points on the Use of Biologicals in Allergic Diseases and Asthma. Allergy Asthma Immunol Res. 2020 Jan;12(1):24-41. doi: 10.4168/aair.2020.12.1.24.
Results Reference
background
PubMed Identifier
28877011
Citation
Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946. doi: 10.1056/NEJMoa1704064. Erratum In: N Engl J Med. 2019 May 23;380(21):2082.
Results Reference
background
PubMed Identifier
17088140
Citation
Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, Holtappels G, Tavernier J, van Cauwenberge P, Bachert C. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006 Nov;118(5):1133-41. doi: 10.1016/j.jaci.2006.05.031. Epub 2006 Sep 26.
Results Reference
background
PubMed Identifier
15813802
Citation
Fokkens W, Lund V, Bachert C, Clement P, Helllings P, Holmstrom M, Jones N, Kalogjera L, Kennedy D, Kowalski M, Malmberg H, Mullol J, Passali D, Stammberger H, Stierna P; EAACI. EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy. 2005 May;60(5):583-601. doi: 10.1111/j.1398-9995.2005.00830.x. No abstract available.
Results Reference
background
PubMed Identifier
17084217
Citation
Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, Adinoff AD, Bachert C, Borish L, Chinchilli VM, Danzig MR, Ferguson BJ, Fokkens WJ, Jenkins SG, Lund VJ, Mafee MF, Naclerio RM, Pawankar R, Ponikau JU, Schubert MS, Slavin RG, Stewart MG, Togias A, Wald ER, Winther B; Rhinosinusitis Initiative. Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol. 2006 Nov;118(5 Suppl):S17-61. doi: 10.1016/j.jaci.2006.09.005.
Results Reference
background
PubMed Identifier
27677865
Citation
Leaker BR, Malkov VA, Mogg R, Ruddy MK, Nicholson GC, Tan AJ, Tribouley C, Chen G, De Lepeleire I, Calder NA, Chung H, Lavender P, Carayannopoulos LN, Hansel TT. The nasal mucosal late allergic reaction to grass pollen involves type 2 inflammation (IL-5 and IL-13), the inflammasome (IL-1beta), and complement. Mucosal Immunol. 2017 Mar;10(2):408-420. doi: 10.1038/mi.2016.74. Epub 2016 Sep 28.
Results Reference
background
PubMed Identifier
24331461
Citation
Yan M, Pamp SJ, Fukuyama J, Hwang PH, Cho DY, Holmes S, Relman DA. Nasal microenvironments and interspecific interactions influence nasal microbiota complexity and S. aureus carriage. Cell Host Microbe. 2013 Dec 11;14(6):631-40. doi: 10.1016/j.chom.2013.11.005.
Results Reference
background
PubMed Identifier
16055882
Citation
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available.
Results Reference
background
PubMed Identifier
22743675
Citation
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27.
Results Reference
background
PubMed Identifier
27214047
Citation
Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016 Jul;13(7):581-3. doi: 10.1038/nmeth.3869. Epub 2016 May 23.
Results Reference
background
PubMed Identifier
22556368
Citation
Pruesse E, Peplies J, Glockner FO. SINA: accurate high-throughput multiple sequence alignment of ribosomal RNA genes. Bioinformatics. 2012 Jul 15;28(14):1823-9. doi: 10.1093/bioinformatics/bts252. Epub 2012 May 3.
Results Reference
background
PubMed Identifier
23193283
Citation
Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glockner FO. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6. doi: 10.1093/nar/gks1219. Epub 2012 Nov 28.
Results Reference
background
PubMed Identifier
30558668
Citation
Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. Microbiome. 2018 Dec 17;6(1):226. doi: 10.1186/s40168-018-0605-2.
Results Reference
background
PubMed Identifier
33225342
Citation
Wilson N, Zhao N, Zhan X, Koh H, Fu W, Chen J, Li H, Wu MC, Plantinga AM. MiRKAT: kernel machine regression-based global association tests for the microbiome. Bioinformatics. 2021 Jul 12;37(11):1595-1597. doi: 10.1093/bioinformatics/btaa951.
Results Reference
background
PubMed Identifier
25516281
Citation
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8.
Results Reference
background
PubMed Identifier
27513472
Citation
Le Cao KA, Costello ME, Lakis VA, Bartolo F, Chua XY, Brazeilles R, Rondeau P. MixMC: A Multivariate Statistical Framework to Gain Insight into Microbial Communities. PLoS One. 2016 Aug 11;11(8):e0160169. doi: 10.1371/journal.pone.0160169. eCollection 2016.
Results Reference
background
Citation
Alving, K., Anolik, R., Crater, G. et al. Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma. Pulm Ther 3, 207-218 (2017). https://doi.org/10.1007/s41030-017-0032-8
Results Reference
background

Learn more about this trial

Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps

We'll reach out to this number within 24 hrs